Feasibility phase

Over 55 million people worldwide suffer from dementia, mostly caused by Alzheimer‘s disease. Dementia has a devastating impact on those affected, their families and the economy. New drugs promise to slow down this development. However, healthcare systems are not currently able to detect Alzheimer‘s disease with the necessary acuracy on a broad scale and at an early stage. The ki-alz-2 project team aims to solve this problem with the help of artificial intelligence, significantly improving early detection of dementia and reliable classification of the cause of the disease.

Transforming Dementia Diagnosis with Artificial Intelligence

The team uses a unique and innovative analysis method with data from various sources (for example imaging and memory testing) for precise and personalised dementia diagnostics. Within the GO-Bio initial feasibility phase, the focus is on improving the diagnostic algorithm and integrating it into a cloud-based application. The excellent performance of ki-alz under controlled study conditions is to be confirmed under realistic hospital conditions. This is the basis for a spinoff. Ki-alz-2 enables precise, early diagnosis of dementia, which is crucial for new therapies.

Conceptual phase

Increasing life expectancy throughout the world is leading to a rapid increase in chronic diseases such as dementia, which affects around 55 million people. This has serious consequences for those affected, their environment and health systems. In recent years there have been ground-breaking advances in the treatment of Alzheimer’s disease, the most common cause of dementia. New antibody drugs that are only effective in early stages are about to be approved. However, there is a lack of precise and scalable diagnostic procedures for effective use in routine care. The ki-alz data analytics platform is designed to help close this gap. The integration of diagnostic data, which is evaluated in combination with the help of artificial intelligence (AI), enables reliable and early diagnosis based on objective data. In the exploratory phase various possibilities for exploiting the project idea will be examined. Interviews and market analyses are carried out in order to identify potential customers and analyse the competitive situation. A patent strategy will be developed and an FTO analysis will be carried out to check the feasibility of the idea. In addition, the future composition of the team is planned. The unique and innovative approach to integrating and interpreting diagnostically significant data for Alzheimer’s disease using AI will create significant value for the healthcare system.

Detailed information about all phase 4 projects